A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma.

Trial Profile

A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Methotrexate (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Busulfan; Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
  • Indications B cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2013 Planned end date changed from 1 Jun 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 04 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Planned end date changed from 1 Jun 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top